The Ligase Enzyme Market is anticipated to record a CAGR of nearly 5.5% during the forecast period.
The COVID-19 pandemic had a notable effect on the ligases enzyme market during the pandemic period. There were many research studies providing insight into the applications of ligases enzyme for identifying potential targets of therapeutic strategies against COVID-19 that significantly impacted the market's growth. For instance, the NCBI article published in April 2021 mentioned that HECT family members of E3 ligases were likely novel biomarkers for COVID-19, as well as new possible targets of therapeutic strategy easily tested in clinical trials. Such studies proving the potential benefits of ligase enzymes in the therapeutic usage against COVID-19 significantly impacted the market's growth. In addition, the demand for the ligases enzyme is expected to remain intact due to the applications in various studies of mutant strains of COVID-19, thereby boosting the market's growth over the forecast period.
The growth of the ligase enzyme market may be attributed to the increasing prevalence of various infectious diseases and genetic birth disorders due to its potential diagnostic and therapeutic properties. For instance, as per the WHO data published in 2022, an estimated 10.6 million tuberculosis cases were recorded globally in 2021. Thus, the high prevalence rate of people with tuberculosis surges the demand for effective and early diagnosis, thereby driving the ligases enzyme market. Also, another WHO data published in 2022 found that between January 24 and February 6, 2022, approximately 12,368 people tested positive for influenza viruses, with 8,423 (68.1%) being categorized as influenza A and 3,945 (31.9%), as influenza B. There were nearly 2,483 (93.6%) influenza A viruses and 171 (6.4%) influenza A(H1N1) pdm09 subtypes (H3N2). Such incidences of infectious diseases globally are expected to drive the demand for ligases enzyme, thereby contributing to the growth of the market. Similarly, the advent of ligases as therapeutic interventions for cancer is also expected to be one of the crucial driving factors of the market. For instance, an NCBI research study published in March 2022 stated that small ubiquitin-like modifier (SUMO) relation is a reversible post-translational modification that plays an essential role in numerous aspects of cell physiology, including cell cycle regulation, DNA damage repair, and protein trafficking and turnover, both of which are crucial for cell homeostasis. Thus, such research studies proving the effective therapeutic benefits of ligase enzymes for cancer are also expected to boost the market's growth.
However, the risk of the high sensitivity of the enzyme is expected to hinder the market growth.
As per the data from the ACS report published in 2022, it is observed that there will be around 1.91 million new cancer cases in the United States in 2022. Among the cancer cases, cancers of the genital and digestive systems were expected to be the highest, with 395,600 and 343,040 new cases, respectively. Such a high incidence of cancer is expected to drive the demand for effective therapeutics, thereby driving the growth of the ligase enzymes market owing to its potential therapeutic interventional properties.
The increasing funding from government and market players' strategies, such as collaborations and partnerships, are expected to fuel the growth of the studied segment. For instance, in May 2021, QIAGEN NV announced a global partnership with Mirati Therapeutics Inc. to advance the development of a tissue-based KRAS companion diagnostic to detect individuals with malignancies that carry the KRASG12C mutation. The intended companion diagnosis would add to QIAGEN's therascreen KRAS testing lineup for the Rotor-Gene Q MDx instrument, which is based on real-time qualitative PCR. Additionally, the Indian Finance Minister suggested allocating Rs 2.23 lakh crore (USD 2699.9 million) for health and wellbeing in the Union Budget 2021-22. This represents a 137% increase over projected expenditure for healthcare in the 2021 fiscal, and it will significantly alter the Indian healthcare system, particularly through the improvement and modernization of the current diagnostic equipment, such as PCR, in government hospitals.
Factors such as the increasing prevalence of various infectious diseases among the North American population drive the demand for effective diagnostics and therapeutics, thereby expected to drive the growth of the market. For instance, as per the CDC data in March 2022, tuberculosis incidence increased by 9.4% from 2020 to 2021 in the United States. Also, the article published by VDH in 2022 mentioned that the incidence rate of tuberculosis in Mexico was nearly 20 per 100,000 persons annually. Additionally, the report published by Tand F Journal in March 2022 mentioned that the incidence rate of tuberculosis among the Canadian population was 4.7 per 100,000 persons annually. Such high incidences of infectious diseases are expected to drive the demand for ligases enzyme, thereby contributing to the market's growth over the forecast period.
Moreover, the increasing market players' activities, such as partnerships, collaborations, and others, are expected to fuel the market growth in this region. For instance, in October 2022, Takara Bio partnered with BioExcel Diagnostics to develop and validate a new throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time PCR automation technology and reagents such as ligases from Takara Bio.
Thus, the high prevalence of infectious diseases, rising market player activities, and the presence of key market players are expected to drive the growth of the market in this region.
This product will be delivered within 2 business days.
The COVID-19 pandemic had a notable effect on the ligases enzyme market during the pandemic period. There were many research studies providing insight into the applications of ligases enzyme for identifying potential targets of therapeutic strategies against COVID-19 that significantly impacted the market's growth. For instance, the NCBI article published in April 2021 mentioned that HECT family members of E3 ligases were likely novel biomarkers for COVID-19, as well as new possible targets of therapeutic strategy easily tested in clinical trials. Such studies proving the potential benefits of ligase enzymes in the therapeutic usage against COVID-19 significantly impacted the market's growth. In addition, the demand for the ligases enzyme is expected to remain intact due to the applications in various studies of mutant strains of COVID-19, thereby boosting the market's growth over the forecast period.
The growth of the ligase enzyme market may be attributed to the increasing prevalence of various infectious diseases and genetic birth disorders due to its potential diagnostic and therapeutic properties. For instance, as per the WHO data published in 2022, an estimated 10.6 million tuberculosis cases were recorded globally in 2021. Thus, the high prevalence rate of people with tuberculosis surges the demand for effective and early diagnosis, thereby driving the ligases enzyme market. Also, another WHO data published in 2022 found that between January 24 and February 6, 2022, approximately 12,368 people tested positive for influenza viruses, with 8,423 (68.1%) being categorized as influenza A and 3,945 (31.9%), as influenza B. There were nearly 2,483 (93.6%) influenza A viruses and 171 (6.4%) influenza A(H1N1) pdm09 subtypes (H3N2). Such incidences of infectious diseases globally are expected to drive the demand for ligases enzyme, thereby contributing to the growth of the market. Similarly, the advent of ligases as therapeutic interventions for cancer is also expected to be one of the crucial driving factors of the market. For instance, an NCBI research study published in March 2022 stated that small ubiquitin-like modifier (SUMO) relation is a reversible post-translational modification that plays an essential role in numerous aspects of cell physiology, including cell cycle regulation, DNA damage repair, and protein trafficking and turnover, both of which are crucial for cell homeostasis. Thus, such research studies proving the effective therapeutic benefits of ligase enzymes for cancer are also expected to boost the market's growth.
However, the risk of the high sensitivity of the enzyme is expected to hinder the market growth.
Ligases Enzyme Market Trends
Polymerase Chain Reaction Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period
Polymerase Chain Reaction (PCR) is expected to dominate the ligases enzyme market through the forecast period. PCR involves a thermostable ligase to join two probes or other molecules together. The increasing prevalence of cancer is expected to contribute to the growth of the studied segment owing to potential therapeutic interventional benefits.As per the data from the ACS report published in 2022, it is observed that there will be around 1.91 million new cancer cases in the United States in 2022. Among the cancer cases, cancers of the genital and digestive systems were expected to be the highest, with 395,600 and 343,040 new cases, respectively. Such a high incidence of cancer is expected to drive the demand for effective therapeutics, thereby driving the growth of the ligase enzymes market owing to its potential therapeutic interventional properties.
The increasing funding from government and market players' strategies, such as collaborations and partnerships, are expected to fuel the growth of the studied segment. For instance, in May 2021, QIAGEN NV announced a global partnership with Mirati Therapeutics Inc. to advance the development of a tissue-based KRAS companion diagnostic to detect individuals with malignancies that carry the KRASG12C mutation. The intended companion diagnosis would add to QIAGEN's therascreen KRAS testing lineup for the Rotor-Gene Q MDx instrument, which is based on real-time qualitative PCR. Additionally, the Indian Finance Minister suggested allocating Rs 2.23 lakh crore (USD 2699.9 million) for health and wellbeing in the Union Budget 2021-22. This represents a 137% increase over projected expenditure for healthcare in the 2021 fiscal, and it will significantly alter the Indian healthcare system, particularly through the improvement and modernization of the current diagnostic equipment, such as PCR, in government hospitals.
North America is Expected to Hold Significant Share in the Market During the Forecast Period
North America is a prominent market due to the well-established end-user industries, such as molecular biology laboratories, research institutes, and pharmaceutical companies.Factors such as the increasing prevalence of various infectious diseases among the North American population drive the demand for effective diagnostics and therapeutics, thereby expected to drive the growth of the market. For instance, as per the CDC data in March 2022, tuberculosis incidence increased by 9.4% from 2020 to 2021 in the United States. Also, the article published by VDH in 2022 mentioned that the incidence rate of tuberculosis in Mexico was nearly 20 per 100,000 persons annually. Additionally, the report published by Tand F Journal in March 2022 mentioned that the incidence rate of tuberculosis among the Canadian population was 4.7 per 100,000 persons annually. Such high incidences of infectious diseases are expected to drive the demand for ligases enzyme, thereby contributing to the market's growth over the forecast period.
Moreover, the increasing market players' activities, such as partnerships, collaborations, and others, are expected to fuel the market growth in this region. For instance, in October 2022, Takara Bio partnered with BioExcel Diagnostics to develop and validate a new throughput and comprehensive method for detecting syndromic-based infectious diseases. The method employs real-time PCR automation technology and reagents such as ligases from Takara Bio.
Thus, the high prevalence of infectious diseases, rising market player activities, and the presence of key market players are expected to drive the growth of the market in this region.
Ligases Enzyme Market Competitor Analysis
The Ligases Enzyme Market is moderately competitive and consists of global as well as local players. Due to technological advancements, small and mid-sized companies focus on market penetration to grab market share. Some companies currently present in the market are ArcticZymes, New England Biolabs, Promega Corporation, QIAGEN, and Takara Bio Inc.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc.
- ArcticZymes Technologies
- Becton, Dickinson and Company
- Creative Enzymes
- Merck KGaA
- New England Biolabs
- Oxford Nanopore Technologies
- Promega Corporation
- QIAGEN
- R&D Systems, Inc
- Takara Bio Inc.
- Thermo Fisher Scientific
Methodology
LOADING...
